Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 12/20 | 0.47 |
| ▸ | MMP9 | P14780 | 12/20 | 0.47 |
| ▸ | MMP12 | P39900 | 11/20 | 0.47 |
| ▸ | MMP2 | P08253 | 8/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24112333 | 0.79 | MMP1 (0.51) | MMP1MMP9MMP12MMP2FLT3 | |
| SCHEMBL26338698 | 0.76 | MMP1 (0.47) | MMP1MMP9MMP12MMP2 | |
| SCHEMBL2897889 | 0.76 | MMP1 (0.47) | MMP1MMP9MMP12MMP2KDM4E | |
| SCHEMBL24019669 | 0.75 | MMP1 (0.49) | MMP1MMP9MMP12MMP2KDM4E | |
| SCHEMBL9354140 | 0.75 | MMP1 (0.60) | MMP1MMP9MMP12MMP2MEN1 | |
| SCHEMBL161785 | 0.74 | KDM4E (0.49) | KDM4EPOLB | |
| SCHEMBL18407327 | 0.73 | ALPL (0.38) | MEN1KMT2AMAPTIMPDH2KDM4E | |
| SCHEMBL21977217 | 0.73 | IMPDH2 (0.39) | MAPTIMPDH2KDM4EALDH1A1GLA | |
| SCHEMBL20206904 | 0.72 | MMP1 (0.56) | MMP1MMP9MMP12MMP2 | |
| SCHEMBL1161224 | 0.72 | MMP1 (0.66) | MMP1MMP9MMP12MMP2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210107917-A1 | BRIDGED BICYCLIC INHIBITORS OF MENIN-MLL AND METHODS OF USE | KURA ONCOLOGY, INC. | 2021-04-15 | — | — | US | disclosed |
| US-10752639-B2 | Bridged bicyclic inhibitors of menin-MLL and methods of use | KURA ONCOLOGY, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20190092783-A1 | BRIDGED BICYCLIC INHIBITORS OF MENIN-MLL AND METHODS OF USE | KURA ONCOLOGY, INC. (US) | 2019-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10752639-B2 | Bridged bicyclic inhibitors of menin-MLL and methods of use | MLLT1, MEN1, MLLT3 | MMP1 4347/4885MMP9 4392/4885MMP12 2408/4885 |
| US-20210107917-A1 | BRIDGED BICYCLIC INHIBITORS OF MENIN-MLL AND METHODS OF USE | MLLT1, MEN1, BMI1 | MMP1 4450/4885MMP9 4395/4885MMP12 2594/4885 |
| US-20190092783-A1 | BRIDGED BICYCLIC INHIBITORS OF MENIN-MLL AND METHODS OF USE | MLLT1, MEN1, BMI1 | MMP1 4450/4885MMP9 4395/4885MMP12 2594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.